CSIMarket
 
Lucid Diagnostics Inc   (NASDAQ: LUCD)
 

Lucid Diagnostics Inc's Customers Performance

LUCD



 
LUCD's Source of Revenues During the corresponding time, Lucid Diagnostics Inc recorded a revenue increase by 26.74 % year on year, sequentially revenue grew by 17.36 %. While revenue at the Lucid Diagnostics Inc 's corporate clients

List of LUCD Customers




for the same period Lucid Diagnostics Inc recorded revenue increase by 26.74 % year on year, sequentially revenue grew by 17.36 %.

List of LUCD Customers

Lucid Diagnostics Inc's Business Units






Lucid Diagnostics Inc's Comment on Sales, Marketing and Customers



The company operates in the medical device and diagnostic markets, focusing on products for detecting changes in the esophagus and sample preservation. Its product portfolio includes EsoGuard and EsoCheck technologies. EsoCheck has received FDA 510(k) clearance for use in both adult and pediatric populations in the United States. EsoGuard is commercialized as a laboratory-developed test (LDT) and has been granted FDA Breakthrough Device Designation. Both EsoCheck and EsoGuard hold CE Mark certification for marketing in European countries. The company licenses intellectual property rights from Case Western Reserve University (CWRU) and pays royalties based on net sales of licensed products. Recent FDA regulatory changes concerning in-vitro diagnostics (IVDs) may affect the enforcement approach for these products.





Lucid Diagnostics Inc’s Comment on Sales, Marketing and Customers


The company operates in the medical device and diagnostic markets, focusing on products for detecting changes in the esophagus and sample preservation. Its product portfolio includes EsoGuard and EsoCheck technologies. EsoCheck has received FDA 510(k) clearance for use in both adult and pediatric populations in the United States. EsoGuard is commercialized as a laboratory-developed test (LDT) and has been granted FDA Breakthrough Device Designation. Both EsoCheck and EsoGuard hold CE Mark certification for marketing in European countries. The company licenses intellectual property rights from Case Western Reserve University (CWRU) and pays royalties based on net sales of licensed products. Recent FDA regulatory changes concerning in-vitro diagnostics (IVDs) may affect the enforcement approach for these products.








LUCD's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Lucid Diagnostics Inc 147.56 5.13 -57.57 82
SUBTOTAL 0.00 0.00 0.00 -

Sources: Lucid Diagnostics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lucid Diagnostics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lucid Diagnostics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.